Abstract

ASSESSMENT OF ANTI-MOG IN SERUM FROM PATIENTS OF MULTIPLESCLEROSIS

Author(s): AMIN MAYSAA NAJAH1*, ABBOODABDULADHEEMYASEEN.2, AL-MASHTA SARMAD ABDULRASOOL

Myelin  oligodendrocyte  glycoprotein  (MOG)  is  considered  as  a  biokmaker  in  multiple  sclerosis  patients,  MOG  is  unique  to  the  brain,  it  is  located  on  the  outer  lamellae  of oligodendroglial  membranes  and  myelin  and  it  is  highly  immunogenic.Objective:In  the  present  study  an  evaluation  of  serum  anti-MOG  antibody  in  relapsing  remitting multiple sclerosis (RRMS)patientswas carried out. Method:Serum levels of anti-MOG were measured by ELISA method after venous blood was collected from forty MS patients and forty healthy subjects as control group. Absorbance was read at a wave length of 450nm using ELISA reader. Anti-MOG antibody level was then calculated by plotting the optical density (O.D.) of each sample against the concentration in the standard curve. Results:A significant difference between serum Anti-MOG  concentration in patients  554.85  ±  39.73pg/ml  and  the  control  group  with  315.20  ±  28.49pg/ml,  (p=0.  0211)  was  found.  Also  Anti-MOG  has  a  negative  correlation  between  age  and concentration (r= -0.12) and significant positive correlation between expanded disability status scale (EDSS) and concentration (r= 0.28). Conclusion:Data for serum level of Anti-MOG Ab are present in this study. They are a basis for the role of Anti-MOG inmultiple sclerosis patients. The present findings showed an increased levels of anti-MOG antibody  in patient group which  may  suggest  the demyelinating  role  of anti-MOG antibody  and  the  importance of  humoral immunity  in  relapsing  remitting  multiple  sclerosis patients. Therefore the data found in this work might be used for further study on the importance of humoral immunity in autoimmune disease like MS.

flyer

ISSN: 2320-3315

ICV :81.58

Get the App